Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma - Quiz - MDSpire

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • By

  • Eric Jurgens

  • Tala Shekarkhand

  • Colin Rueda

  • David Nemirovsky

  • Andriy Derkach

  • Ross S. Firestone

  • Kevin Miller

  • Bruno Almeida Costa

  • Sridevi Rajeeve

  • Alexander M. Lesokhin

  • Neha Korde

  • Carlyn R. Tan

  • Hamza Hashmi

  • Hani Hassoun

  • Kylee Maclachlan

  • Urvi A. Shah

  • Malin Hultcrantz

  • Issam Hamadeh

  • Sergio A. Giralt

  • Gunjan L. Shah

  • Heather J. Landau

  • Michael Scordo

  • Saad Z. Usmani

  • Sham Mailankody

  • Zainab Shahid

  • November 1, 2025

  • 0 min

Share

Original Source(s)

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • by Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross S. Firestone, Kevin Miller, Bruno Almeida Costa, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn R. Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam Hamadeh, Sergio A. Giralt, Gunjan L. Shah, Heather J. Landau, Michael Scordo, Saad Z. Usmani, Sham Mailankody, Zainab Shahid

  • November 1, 2025

Related Content

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China